ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1420	National Cancer Institute	Html	en	Prostate Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease.	hereditary prostate cancer 0.542395 prostate biopsy 0.533126 dutasteride group vs 0.459041 skin cancer 0.446356 prostate cancer period 0.528407 cancer mortality rates 0.459369 prostate volume subgroups 0.508967 Prostate Cancer Events 0.558338 finasteride group versus 0.448086 rat ventral prostate 0.516053 high-grade tumors 0.479135 high-grade cancer 0.454168 prostate cancer-specific mortality 0.525559 occult prostate cancer 0.561891 high-grade prostate cancer 0.548137 prostate preventive effects 0.507979 relative risk reduction 0.446967 radical prostatectomy 0.460894 prostate cancer mortality 0.534065 prostate cancer chemoprevention 0.531007 dietary fat 0.445789 men 0.4492 Cancer Events trial 0.451937 negative prostate biopsy 0.515564	digital rectal examination 0.454846 dutasteride group 0.460003 fat intake 0.450377 Cancer Prevention Trial 0.500983 prostate digital 0.500034 prostate cancer risk 0.564597 placebo group 0.469544 incident prostate cancer 0.532469 Cancer Events study 0.447937 prostate volume 0.517049 absolute risk reduction 0.495169 low biologic risk 0.447169 finasteride group 0.448145 prostate cancer 0.910772 Gleason 0.458954 clinical prostate cancer 0.556069 pancake-appearing prostate 0.508749 Prostate Cancer Prevention 0.595277 prostate cancer. 0.505972 prostate cancer death. 0.562581 statistically significant difference 0.470146 prostate cancers 0.559985 human prostate cancer 0.538634	CLICK HERE
1570	National Cancer Institute	Html	en	Neuroblastoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood neuroblastoma.	cancer treatment 0.566372 neuroblastoma 0.915175 tumor biology 0.626071 malignant tumor cells 0.558857 body 0.647664 chemotherapy 0.49696 PDQ cancer information 0.548139 clinical trials 0.793699 cancer information summary 0.51948 low-risk neuroblastoma 0.514243 clinical trial 0.659456 high-risk neuroblastoma 0.659347 tumor histology 0.510739 favorable tumor biology 0.542334 unfavorable tumor biology 0.522724 treatment clinical trial 0.493293 lymph nodes 0.501542 radiation therapy 0.646669 Treatment Editorial Board 0.49305 neuroblastoma spreads 0.512002 Neuroblastoma Treatment 0.537187 neuroblastoma cell 0.510315 treatment 0.836037 time neuroblastoma 0.52866 cancer cells 0.648207	recurrent neuroblastoma 0.571181 neuroblastoma talk 0.50906 Neuroendocrine tumor cells 0.542579 neuroblastoma cells 0.566453 treatment clinical trials 0.520878 National Cancer Institute 0.53108 tumor cells 0.633055 intermediate-risk neuroblastoma 0.542626 new treatment 0.533829 Progressive/Recurrent Neuroblastoma 0.502026 primary tumor 0.499207 metastatic tumor 0.511477 blood 0.501083 Iodine 131-MIBG therapy 0.54351 bone marrow 0.53977 stage 4S neuroblastoma 0.523743 cancer clinical trials 0.49476 Recurrent CNS Neuroblastoma 0.519837 stem cell rescue 0.505173 tumor 0.835165 treatment options 0.506317 cancer 0.929691 standard treatment 0.535537 metastatic neuroblastoma 0.513574	CLICK HERE
2015	National Cancer Institute	Html	es	Prevención del cáncer de pulmón (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre factores que influirían en el riesgo de presentar cáncer de pulmón y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	cigarrillo encendido 0.533546 voluntarios sanos 0.521783 secciones llamadas lóbulos 0.564444 factor protector 0.54356 rayos x 0.525531 rayos gamma 0.526755 altas cantidades 0.523911 vías respiratorias 0.534485 suplementos vitamina 0.527073 membrana delgada llamada 0.563077 National Cancer Institute 0.526876 Más personas 0.538369 Instituto Nacional 0.548081	antecedentes familiares 0.770813 siguientes factores 0.598507 Physician Data Query 0.601335 gas radón 0.544843 prevención revisa 0.523285 PDQ Prevención 0.542908 siguientes sustancias 0.533013 Menor exposición 0.544963 órganos respiratorios 0.535883 principal causa 0.53309 factores protectores 0.947087 siguientes sumarios 0.567797 suplementos alimenticios 0.525893	CLICK HERE
2079	National Cancer Institute	Html	es	BRCA1 y BRCA2: Riesgo de cáncer y pruebas genéticas	Hoja informativa acerca de los genes BRCA1 y BRCA2, de qué hacer si una persona tiene resultados positivos para una de estas alteraciones, y de las consecuencias de las pruebas genéticas.	with inherited mutations 0.40971 Fanconi anemia 0.442696 general padecerán cáncer 0.476912 Lubinski J 0.414965 Cancer Statistics Review 0.41308 brca1 or brca2 0.539593 largo plazo 0.414755 American Cancer Society 0.413258 posibles perjuicios 0.41059 Biallelic mutations 0.410182 National Comprehensive Cancer 0.413868 Breast Cancer Research 0.418728 with brca1 or 0.423664 Múltiples cánceres 0.410805 mutaciones específicas dañinas 0.471623 brca2 mutations 0.589927 among male brca1 0.421616 or genetic predisposition 0.416124 BRCA2 padecerán 0.44228 gen palb2 0.413362 BRCA1 mutation carriers 0.444383 Estados Unidos 0.427518 padecerán cáncer 0.566332 mutaciones dañinas 0.851633 PubMed Abstract 0.989166	mutation carriers identified 0.410419 seno masculino 0.429589 Clinical Oncology 0.441136 BRCA2 carriers 0.419799 risks among brca1 0.420776 BRCA2 mutation carriers 0.508942 BRCA2 mutations detected 0.422577 contralateral breast 0.413156 National Cancer Institute 0.442375 Cancer Research 0.430441 Breast Cancer Prevention 0.417323 antecedentes familiares 0.783866 or brca2 mutations 0.503006 mutation carriers with 0.423928 breast cancer 0.531052 clinical breast examination 0.410267 mujeres padecerán 0.409393 mujeres portadoras 0.421608 gen brca1 0.536899 asesoría genética 0.435987 cancer risk 0.445775 New England Journal 0.415366 bilateral profiláctica 0.437879 BRCA2 mutations account 0.4223	CLICK HERE
3674	National Cancer Institute	Html	en	About the Genomic Data Sharing (GDS) Policy	Find helpful information about the GDS Policy, including when the policy applies, example projects, and providing informed consent.	data 0.82822 subsequent research 0.542062 scale research projects 0.540547 case-by-case basis 0.523592 large-scale genomic data 0.566607 research 0.652936 research projects 0.576167 intramural research 0.556456 investigators 0.50707 future research 0.572423 genomic data 0.760118 Human Genome Research 0.527144 Sharing Repository list 0.531325 NIH repository 0.489091 research community 0.487992 non-human genomic data 0.67956 NIH-funded research projects 0.531999 broad sharing 0.547642 Intramural investigators 0.494528 Trans-NCI Data Sharing 0.55358 NIH Genomic Data 0.603222 NIH Deputy Director 0.524095 usual data 0.490789 data sharing 0.652134	NCI Scientific Program 0.534443 Rare Disease Act 0.50658 United States 0.504978 sample consent forms 0.527036 NCI-funded research 0.492053 small patient populations 0.504923 sample threshold 0.505219 alternative data sharing 0.62573 appropriate program directors 0.511229 appropriate NCI Program 0.550878 Phenotypic Data Subject 0.531651 intramural scientific director 0.629908 consent forms 0.555547 data sharing plan 0.62329 effective date 0.571535 smaller scale 0.517774 study data 0.489242 NCI Director 0.488407 NIH-designated data repositories 0.533934 data repositories 0.543247 Intramural projects 0.499743 gds policy 0.963933 time points 0.50548 Orphan Drug Act 0.506071	CLICK HERE
16716	National Cancer Institute	Html	en	NCI Cancer Moonshot℠ Public Access and Data Sharing Policy	NCI has established a data sharing policy that supports open, public access to all research and data for projects funded as part of the Cancer Moonshot. Find details on the policy.	Underlying Primary Data 0.835591 National Cancer Advisory 0.204571 Creative Commons 0.266314 Cancer Moonshotâ„  0.229846 Moonshot Research Project 0.326921 public domain tool 0.238273 extramural Cancer Moonshot 0.217832 Cancer Moonshot beginning 0.210573 cancer research 0.226051 Data Sharing Repositories 0.219342 underlying data 0.223365 NIH Sharing Policies 0.206938 Genomic Data Sharing 0.238331 Moonshot Research Projects 0.712789 Cancer Moonshotâ„  Research 0.221203 NIH Data Sharing 0.283755 National Cancer Institute 0.205263 Cancer Moonshot Projects 0.211704 public access 0.827988	Blue Ribbon Panel 0.23172 Cancer Moonshot Research 0.963477 independent data access 0.222133 data sharing policies 0.240205 Public Access Policy. 0.214656 nih public access 0.329101 Genomic Data Commons 0.208284 Enhanced Data Sharing 0.250631 Public Access Policy 0.237717 NCI-Supported Cancer Moonshot 0.379658 appropriate Public Access 0.254192 cancer research projects 0.217712 NCI researchers 0.205129 NCI intramural Cancer 0.231006 Data Sharing Policy 0.330676 Rule.7 Underlying Primary 0.217644 Data Sharing Plan 0.965755 intramural Cancer Moonshot 0.258314 Cancer Moonshot Public 0.244424	CLICK HERE
16831	National Cancer Institute	Html	en	Functional Genomics Research	NCI's Center for Cancer Genomics uses functional genomics to understand the impact of cancer genes and pathways, and how to target them effectively.	CTD² Network 0.438678 Wellcome Trust Sanger 0.539692 Cancer Target 0.513795 genome-wide techniques 0.446676 new ideas 0.464401 functional genomics 0.975263 genomic vulnerabilities 0.510701 functional genomics experiments 0.70252 clinical data 0.51781 abnormal proliferation 0.447258 functional cancer genomics 0.735243 functional genomic approaches 0.609867 new methods 0.442531 cutting-edge organoid 0.535662 Driver Discovery 0.445569 research community 0.441075 cancer care 0.532833 CTD2 Network 0.523145 structural genomics research 0.72197 large-scale genomic datasets 0.600198 cancer work 0.514288 cell models 0.464098 available drugs 0.442916 functional genomics research 0.95801 human tumors 0.440224	CRISPR-Cas9 technology 0.437797 particular genetic alterations 0.563867 gene perturbation experiments 0.559111 Cancer Research UK 0.609166 tumor organoid cultures 0.651279 cancer cells 0.526612 cancer cell lines 0.623629 publicly available bank 0.544919 Cancer Model Development 0.602943 genetic abnormalities 0.444289 new compounds 0.443968 Genome Characterization Pipeline 0.5568 structural genomics studies 0.680281 CCG researchers 0.496817 high-throughput drug screens 0.551758 clinical care 0.437267 publishing novel results 0.53823 patient biopsies 0.451112 petri dishes 0.439826 cancer genes 0.514196 cancer development 0.502413 next-generation cancer models 0.753989 Hubrecht Organoid Technology 0.640694 cancer biology 0.533186	CLICK HERE
16840	National Cancer Institute	Html	en	Companies Formed by PIs of the NCI Alliance for Nanotechnology in Cancer	The NCI Alliance for Nanotechnology in Cancer has continued to translate solutions from the bench to products. Find out the companies that have been formed by Alliance funded research.	clinical products 0.627038 Alliance members 0.614849 academic laboratories 0.654334 for-profit partners 0.714957 start-ups 0.300298 clinical communities 0.60175 venture capital funds 0.950483 investigators 0.301645 partnerships 0.289977 start-up companies 0.650807 patents 0.29414 large pharmaceutical companies 0.926075	translational research 0.68727 significant investment 0.618191 Alliance PIs 0.780886 efficient development 0.679103 IP 0.327964 Alliance model 0.651092 services 0.276826 start-up companies. 0.723832 technologies 0.28746 biotechnology firms 0.63767 form 0.28731 discoveries 0.300415	CLICK HERE
16848	National Cancer Institute	Html	en	Treatment and Therapy	Nanotechnology offers the means to target therapies directly and selectively to cancerous cells and neoplasms. With these tools, clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno- and gene therapies to the tumor. Futhermore, surgical resection of tumors can be guided and enhanced by way of nanotechnology tools. Find out how nanotechnology will offer the next generation of our therapeutic arsenal to the patient.	cancer treatment 0.854097 tumor type 0.82492 tumor tissues 0.889211 Cancer therapies 0.820703 large surface area 0.827043 nanoparticles 0.943843 superficial tumor 0.871555 nanotechnology cancer therapy 0.925806 multiple myeloma patients 0.821624 RNA-based genetic therapeutics 0.82576 cancer therapeutics 0.879587 vivo RNA nanoparticle 0.839578 nucleic acids 0.851966 electromagnetic radiation modalities 0.829021 cancer immunotherapy deepens 0.869884 artificial antigen 0.824529 Host Cell Response 0.906892 radiation therapy 0.999924 Standalone nanoparticle vaccines 0.835115 multiple dendritic cell 0.822099 conventional radiation therapy 0.856977 tumor vasculature permeability 0.888964 Cancer Nanotechnology Excellence 0.870289 tumor mass 0.82439	photodynamic therapy 0.836532 Cancer Nanotechnology awardees 0.958295 cancer cells 0.999243 external radiation sources 0.839028 small molecule compounds 0.820814 Cancer Therapy Center 0.956254 form Cherenkov radiation 0.829553 tumor accumulation 0.82268 atomic number nanoparticles 0.859022 Biology Cancer Center 0.860679 current radiotherapy dosage 0.82716 delivery 0.878526 combination drug delivery 0.856304 current treatment modalities 0.839227 superficial tumor sites 0.867918 innovative nanoparticle packages 0.854373 Gene silencing therapeutics 0.826818 tissue tumor targets 0.869042 electromagnetic radiation 0.829381 nanomaterial-based delivery platforms 0.862296 external electromagnetic radiation 0.823812 tumor 0.913691 tumor microenvironment 0.865684 deep tissue tumors 0.824773	CLICK HERE
17234	National Cancer Institute	Html	en	Adding Immune-based Treatments to Standard Glioblastoma Therapy	This clinical trial is testing standard therapy (surgery, radiation and temozolomide) plus immunotherapy with pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.	immune checkpoint inhibitor 0.991382 Dr. Gilbert 0.728039 tumor tissue 0.405841 trial contact information 0.29929 experimental vaccine 0.247456 1-year overall survival 0.300393 NCI’s Cancer 0.233291 Treating Patients 0.208707 little tumor tissue 0.376059 standard therapy plus 0.329661 immune response 0.550076 NCI Clinical Trials 0.330246 chemotherapy drug temozolomide 0.399109 cancer treatment vaccine 0.66133 primary brain tumor 0.428278 Cancer Research 0.215559 clinical trials 0.480839	slow tumor growth 0.416918 partially randomized phase 0.30891 patients 0.251176 Mark R. Gilbert 0.399405 tumor-specific vaccine 0.249165 experimental cancer treatment 0.582716 immune checkpoint inhibitors 0.542772 microscopic tumor 0.266367 newly diagnosed glioblastoma 0.842005 Current standard therapy 0.36143 placebo vaccine 0.253985 immunotherapy drug pembrolizumab 0.351275 median survival time 0.347591 protocol summary 0.359999 radiation therapy 0.342013 standard therapy 0.747186	CLICK HERE